Hematologic Malignancies Clinical Trial
Official title:
Elderly Cancer Patient: ELCAPA Cohort Survey
The management of older patients with cancer has become a major public health concern in
Western countries because of the aging of the population and steady increase in cancer
incidence with advancing age. Cancer treatment of aged patients is complex due to
comorbidities, polypharmacy and functional status. The heterogeneity of the older population
in terms of comorbidities and functional status may explain the difficulty in establishing
management recommendations.
Study hypothesis is that a geriatric consultation using Geriatric Assessment (GA) can
evaluate patient's resource and strengths, in order to help oncologist to define the most
effective treatment. The GA developed by geriatricians and recommended by the International
Society of Geriatric Oncology (SIOG), is a multidimensional assessment of general health
status; comorbidities; functional status; nutritional, cognitive, psychological, and social
parameters; and medications. The GA uses validated geriatric scales to produce an inventory
of problems, which can then serve to develop an individualized geriatric intervention plan;
it may be an important step in selecting elderly patients for cancer screening and
treatment.
The objectives are:
- To assess the role of GA for decision making process for older patients with cancer
- To identify geriatric and oncologic factors associated with overall survival, treatment
feasibility, toxicities, morbidities
- To develop and/or validate screening tests for frailty in geriatric oncology
- To develop and validate frailty classifications
Method: The ELCAPA (ELderly CAncer PAtient) survey is a French multicentric prospective
study that includes all patients age 70 years or older who has a diagnosis of solid cancer
or hematologic malignancies in French hospitals
n/a
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05433090 -
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
|
N/A | |
| Completed |
NCT00061620 -
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
|
Phase 1 | |
| Enrolling by invitation |
NCT02473757 -
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
|
||
| Recruiting |
NCT02032446 -
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01203722 -
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT00780052 -
Infusional C-myb ASODN in Advanced Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04098393 -
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
|
Phase 1 | |
| Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
| Completed |
NCT04538599 -
RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05849207 -
Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant
|
Phase 1 | |
| Not yet recruiting |
NCT05028478 -
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02494258 -
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
|
Phase 2 | |
| Completed |
NCT03212560 -
Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
|
||
| Active, not recruiting |
NCT02600208 -
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
|
Phase 2/Phase 3 | |
| Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT01949545 -
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment
|
Phase 1 | |
| Completed |
NCT01930981 -
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
|
N/A | |
| Recruiting |
NCT01351545 -
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
|